申请人:High Point Pharmaceuticals, LLC
公开号:EP2233470A1
公开(公告)日:2010-09-29
Novel compounds of formula I-9:
which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.
式 I-9 的新型化合物:
定义了与组胺 H3 受体相互作用的新型化合物。这些化合物特别适用于治疗组胺 H3 相互作用有益的各种疾病或病症。因此,这些化合物可用于治疗中枢神经系统、周围神经系统、心血管系统、肺部系统、胃肠道系统和内分泌系统等疾病。这些新型化合物的核心是一个 6 个成员的芳香环,环中至少含有一个氮原子和两个碳原子,在环的其余位置,要么有一个碳原子,要么有一个氮原子。